These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16409550)

  • 1. Lrrk2 R1441 substitution and progressive supranuclear palsy.
    Ross OA; Whittle AJ; Cobb SA; Hulihan MM; Lincoln SJ; Toft M; Farrer MJ; Dickson DW
    Neuropathol Appl Neurobiol; 2006 Feb; 32(1):23-5. PubMed ID: 16409550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany.
    Madzar D; Schulte C; Gasser T
    Eur J Neurol; 2009 Nov; 16(11):1230-2. PubMed ID: 19538213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial aggregation of parkinsonism in progressive supranuclear palsy.
    Donker Kaat L; Boon AJ; Azmani A; Kamphorst W; Breteler MM; Anar B; Heutink P; van Swieten JC
    Neurology; 2009 Jul; 73(2):98-105. PubMed ID: 19458322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel LRRK2 mutations in Parkinsonism.
    Trinh J; Guella I; McKenzie M; Gustavsson EK; Szu-Tu C; Petersen MS; Rajput A; Rajput AH; McKeown M; Jeon BS; Aasly JO; Bardien S; Farrer MJ
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1119-21. PubMed ID: 26213354
    [No Abstract]   [Full Text] [Related]  

  • 5. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.
    Sanchez-Contreras M; Heckman MG; Tacik P; Diehl N; Brown PH; Soto-Ortolaza AI; Christopher EA; Walton RL; Ross OA; Golbe LI; Graff-Radford N; Wszolek ZK; Dickson DW; Rademakers R
    Mov Disord; 2017 Jan; 32(1):115-123. PubMed ID: 27709685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP.
    Spanaki C; Latsoudis H; Plaitakis A
    Neurology; 2006 Oct; 67(8):1518-9. PubMed ID: 17060595
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
    Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
    Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three sib-pairs of autopsy-confirmed progressive supranuclear palsy.
    Fujioka S; Sanchez Contreras MY; Strongosky AJ; Ogaki K; Whaley NR; Tacik PM; van Gerpen JA; Uitti RJ; Ross OA; Wszolek ZK; Rademakers R; Dickson DW
    Parkinsonism Relat Disord; 2015 Feb; 21(2):101-5. PubMed ID: 25443551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study.
    Jabbari E; Koga S; Valentino RR; Reynolds RH; Ferrari R; Tan MMX; Rowe JB; Dalgard CL; Scholz SW; Dickson DW; Warner TT; Revesz T; Höglinger GU; Ross OA; Ryten M; Hardy J; Shoai M; Morris HR;
    Lancet Neurol; 2021 Feb; 20(2):107-116. PubMed ID: 33341150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
    Zimprich A; Biskup S; Leitner P; Lichtner P; Farrer M; Lincoln S; Kachergus J; Hulihan M; Uitti RJ; Calne DB; Stoessl AJ; Pfeiffer RF; Patenge N; Carbajal IC; Vieregge P; Asmus F; Müller-Myhsok B; Dickson DW; Meitinger T; Strom TM; Wszolek ZK; Gasser T
    Neuron; 2004 Nov; 44(4):601-7. PubMed ID: 15541309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers.
    Vilas D; Sharp M; Gelpi E; Genís D; Marder KS; Cortes E; Vonsattel JP; Tolosa E; Alcalay RN
    Mov Disord; 2018 Feb; 33(2):335-338. PubMed ID: 29119599
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetics of Progressive Supranuclear Palsy: A Review.
    Wen Y; Zhou Y; Jiao B; Shen L
    J Parkinsons Dis; 2021; 11(1):93-105. PubMed ID: 33104043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains.
    Ingelsson M; Ramasamy K; Russ C; Freeman SH; Orne J; Raju S; Matsui T; Growdon JH; Frosch MP; Ghetti B; Brown RH; Irizarry MC; Hyman BT
    Acta Neuropathol; 2007 Nov; 114(5):471-9. PubMed ID: 17721707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy.
    Ros R; Thobois S; Streichenberger N; Kopp N; Sánchez MP; Pérez M; Hoenicka J; Avila J; Honnorat J; de Yébenes JG
    Arch Neurol; 2005 Sep; 62(9):1444-50. PubMed ID: 16157753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease.
    Toft M; Mata IF; Ross OA; Kachergus J; Hulihan MM; Haugarvoll K; Stone JT; Blazquez M; Gibson JM; Aasly JO; White LR; Lynch T; Adler CH; Gwinn-Hardy K; Farrer MJ
    Mov Disord; 2007 Feb; 22(3):389-92. PubMed ID: 17216639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism.
    Ross OA; Spanaki C; Griffith A; Lin CH; Kachergus J; Haugarvoll K; Latsoudis H; Plaitakis A; Ferreira JJ; Sampaio C; Bonifati V; Wu RM; Zabetian CP; Farrer MJ
    Parkinsonism Relat Disord; 2009 Jul; 15(6):466-7. PubMed ID: 18952485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
    Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
    Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
    Rajput A; Dickson DW; Robinson CA; Ross OA; Dächsel JC; Lincoln SJ; Cobb SA; Rajput ML; Farrer MJ
    Neurology; 2006 Oct; 67(8):1506-8. PubMed ID: 17060589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.